New Enterprise Associates

News, insights, analysis and data

← Back to New Enterprise Associates profile

New Enterprise Associates related stories

All articles and analysis

  • NextNav snags $70 mln Series D
    Iris Dorbian- 24 July 2014

    NextNav has secured $70 million in Series D financing. New Enterprise Associates and Oak Investment Partners led the round with participation from Columbia Capital, Telcom Ventures and Goldman Sachs Investment Partners. In conjunction with the funding, Peter Barris, managing general partner at NEA, and Bandel Carano, managing partner at Oak, have been named to NextNav's board of directors. Based in Sunnyvale, Calif. and McLean, VA, NextNav is a provider of location solutions for indoor and urban environments.

  • Beanstalk nets $2 mln seed
    Iris Dorbian- 23 July 2014

    Beanstalk said Wednesday that it has closed $2 million in seed funding. New Enterprise Associates led the round with participation from EPIC Ventures, Deep Fork Capital and former Wall Street executive and investor Jim Engebretsen. Headquartered in Salt Lake City, Beanstalk is an SaaS-based tax platform for small-to-medium-sized businesses and their advisors.

  • Nevada PERS bets more on venture: VCJ
    Mark Boslet- 23 July 2014

    The Public Employees’ Retirement System of Nevada has stepped up its venture capital investing over the past couple of years with commitments to Battery Ventures, Canaan Partners and Technology Crossover Ventures.

  • Nevada PERS bets more on venture: VCJ
    Mark Boslet- 23 July 2014

    The Public Employees’ Retirement System of Nevada has stepped up its venture capital investing over the past couple of years with commitments to Battery Ventures, Canaan Partners and Technology Crossover Ventures.

  • Adams Street CEO French to work full-time through at least 2017
    Brad Meikle- 22 July 2014

    Adams Street Partners Chief Executive Officer T. Bondurant French will remain at the advisory firm in a full-time capacity through at least 2017, when he turns 65, according to a letter distributed to limited partners.

  • Atlas Ventures and NEA back Synlogic
    Iris Dorbian- 22 July 2014

    Synlogic said Tuesday that it has received $29.4 million in Series A funding. Atlas Venture and New Enterprise Associates led the round. In conjunction with the funding, Dr. Peter Barrett and Dr. Ankit Mahadevia of Atlas Venture and Ed Mathers of NEA have been appointed to Synlogic's board of directors. Based in Cambridge, Mass., Synlogic is a biotech firm focused on developing therapeutic microbes.

  • Fund performance: Nevada PERS bets more on venture
    Mark Boslet- 21 July 2014

    LP favors large funds, wins strong performances from Battery, Summit, NEA

  • Cerecor closes first tranche of $32 mln Series B
    Iris Dorbian- 21 July 2014

    Cerecor has closed on the initial tranche of a $32 million Series B funding. New Enterprise Associates, Apple Tree Partners and MPM Capital led the round. Based in Baltimore, Cerecor is a biopharmaceutical firm focused on developing treatments for patients suffering from nervous system disorders.

  • Roka Bioscience raises $60 mln for IPO
    Iris Dorbian- 17 July 2014

    Roka Bioscience has launched its IPO after pricing its 5 million shares at $12 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "ROKA." BofA Merrill Lynch and Leerink Partners are the lead underwriters. Based in Warren, NJ, Roka Bioscience is a molecular diagnostics firm focused on detecting foodborne pathogens. Its backers include OrbiMed Advisors, NEA and TPG Biotech.

  • Roka Bioscience raises $60 mln for IPO
    Iris Dorbian- 17 July 2014

    Roka Bioscience has launched its IPO after pricing its 5 million shares at $12 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "ROKA." BofA Merrill Lynch and Leerink Partners are the lead underwriters. Based in Warren, NJ, Roka Bioscience is a molecular diagnostics firm focused on detecting foodborne pathogens. Its backers include OrbiMed Advisors, NEA and TPG Biotech.